Novo Nordisk Invests $221 Million in New Danish Plant to Enhance Supply Chain

Novo Nordisk's Pharmatech unit is investing DKK 1.5 billion ($221 million) in a new raw materials factory in Køge, Denmark.
The investment aims to boost the company's supply chain capabilities.
This move is part of Novo Nordisk's efforts to address supply challenges, particularly for its drug semaglutide.
Semaglutide is a synthetic peptide used for treating conditions such as obesity, overweight, and type 2 diabetes mellitus.
The new plant will support the production of semaglutide and other drugs, enhancing Novo Nordisk's manufacturing capacity and reliability.